New study tests whether extra material in breast reconstruction is worth it

NCT ID NCT05316324

Ongoing Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two methods of prepectoral breast reconstruction after mastectomy for breast cancer: one using acellular dermal matrix (ADM) and one without. The goal is to see if using ADM leads to fewer major complications like infection or implant removal within 90 days. About 353 women aged 21-60 are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acellular dermal matrix (ADM)
What this could lead to: If successful, this study could show that using ADM in breast reconstruction does not reduce complications, potentially simplifying the procedure and reducing costs.
What could go wrong: This is a single-center trial, and results may not apply to all patients or surgical techniques. The study only looks at short-term complications, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Rockville Centre, New York, 11553, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.